Diffuse Large B-Cell Lymphoma (DLBCL) clinical trials in Colorado
21 active Diffuse Large B-Cell Lymphoma (DLBCL) trials with a site in Colorado. Describe your situation to see which ones look like a fit.
- A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
- A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
- A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
- Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
- Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients
- DALY II USA/ MB-CART2019.1 for DLBCL
- A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
- A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
- A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- A Phase 1 Study of IM-1021 in Participants With Advanced Cancer
- Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- A Study of NX-1607 in Adults With Advanced Malignancies
- Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
- A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
- Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma
Guides for people searching for a trial
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.